JP2010500993A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500993A5
JP2010500993A5 JP2009524665A JP2009524665A JP2010500993A5 JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5 JP 2009524665 A JP2009524665 A JP 2009524665A JP 2009524665 A JP2009524665 A JP 2009524665A JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5
Authority
JP
Japan
Prior art keywords
optionally substituted
triazole
mercapto
phenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500993A (ja
JP5480623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017996 external-priority patent/WO2008021364A2/en
Publication of JP2010500993A publication Critical patent/JP2010500993A/ja
Publication of JP2010500993A5 publication Critical patent/JP2010500993A5/ja
Application granted granted Critical
Publication of JP5480623B2 publication Critical patent/JP5480623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524665A 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物 Expired - Fee Related JP5480623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83830606P 2006-08-17 2006-08-17
US60/838,306 2006-08-17
PCT/US2007/017996 WO2008021364A2 (en) 2006-08-17 2007-08-14 Triazole compounds that modulate hsp90 activity

Publications (3)

Publication Number Publication Date
JP2010500993A JP2010500993A (ja) 2010-01-14
JP2010500993A5 true JP2010500993A5 (enExample) 2010-10-21
JP5480623B2 JP5480623B2 (ja) 2014-04-23

Family

ID=38924466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524665A Expired - Fee Related JP5480623B2 (ja) 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物

Country Status (6)

Country Link
US (1) US8188075B2 (enExample)
EP (1) EP2054059A2 (enExample)
JP (1) JP5480623B2 (enExample)
AU (1) AU2007284537B2 (enExample)
CA (1) CA2659425C (enExample)
WO (1) WO2008021364A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298748B1 (en) 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
AU2007267803B2 (en) 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653329C (en) 2006-05-25 2018-01-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
EP2034995A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Method for treating proliferative disorders associated with protooncogene products
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
CN101679319B (zh) * 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
WO2009158026A1 (en) 2008-06-27 2009-12-30 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011133521A2 (en) * 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
JP2014520808A (ja) 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Hsp90阻害化合物を用いた癌の治療
JP2014534228A (ja) * 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とhsp90阻害剤の組合せ療法
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2586080A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
EP2298748B1 (en) * 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP5044730B2 (ja) * 2005-03-09 2012-10-10 日本化薬株式会社 新規なhsp90阻害剤
EP1928846B1 (en) * 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
EP2034995A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Method for treating proliferative disorders associated with protooncogene products
AU2007267803B2 (en) * 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653329C (en) * 2006-05-25 2018-01-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
TW200804313A (en) * 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
TW200806637A (en) * 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity

Similar Documents

Publication Publication Date Title
JP2008520702A5 (enExample)
JP2009538320A5 (enExample)
RU2612958C2 (ru) 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
JP2009538322A5 (enExample)
JP2009538321A5 (enExample)
JP2013508378A5 (enExample)
JP2010536753A5 (enExample)
JP2010518085A5 (enExample)
US6436966B1 (en) Adenosine A3 receptor antagonists
AU2012200157B2 (en) Method for treating proliferative disorders associated with protooncogene products
CA2653336C (en) Method for treating non-hodgkin's lymphoma
JP2020527560A5 (enExample)
AU2007267843A1 (en) Method for treating proliferative disorders associated with protooncogene products
JP2017505762A5 (enExample)
JP2008500992A5 (enExample)
RU2006126663A (ru) Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
ZA200305619B (en) Substituted triazole diamine derivatives as kinase inhibitors.
JP2010522750A5 (enExample)
JP2014526500A5 (enExample)
US20130172333A1 (en) Formulation and dosing of hsp90 inhibitory compounds
JP2013501749A5 (enExample)
JP2010540602A5 (enExample)
CA2657550A1 (en) Benzimidazole derivatives as selective acid pump inhibitors
JP2010540666A5 (enExample)
JP2008537930A5 (enExample)